首页> 外文期刊>The American Journal of Cardiology >Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction
【24h】

Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction

机译:对ST段抬高型心肌梗死患者冠状动脉内和静脉内糖蛋白IIb / IIIa抑制剂给药的随机对照试验的荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Glycoprotein IIb/IIIa receptor inhibitors (GPIs) have been widely adopted as an adjuvant regimen during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction, but whether intracoronary administration of these potent antiplatelet agents conveys better efficacy and safety over the intravenous route has not been well addressed. A meta-analysis was performed by a systematic search of the published research for randomized controlled trials comparing intracoronary versus intravenous administration of GPIs in patients with ST-segment elevation myocardial infarction. Eight studies involving 686 patients in the intracoronary arm and 660 in the intravenous arm met the inclusion criteria. Postprocedural Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow (odds ratio [OR] 1.46, 95% confidence interval [CI] 1.08 to 1.98, p <0.05) and myocardial reperfusion grade 2 or 3 (OR 1.78, 95% CI 1.29 to 2.46, p <0.001) were markedly more often achieved in patients who received intracoronary boluses of GPIs than those receiving the intravenous strategy. Intracoronary administration resulted in a reduced incidence of mortality (OR 0.44, 95% CI 0.21 to 0.92, p <0.05), target vessel revascularization (OR 0.53, 95% CI 0.29 to 0.99, p <0.05), and the composite end point of major adverse cardiac events (OR 0.48, 95% CI 0.31 to 0.76, p <0.005) at 30-day follow-up. No significant difference was found in terms of major or minor bleeding (OR 1.14, p = 0.71, and OR 0.86, p = 0.47 respectively). In conclusion, intracoronary administration of GPIs yielded favorable outcomes in postprocedural blood flow restoration and 30-day clinical prognosis in patients with ST-segment elevation myocardial infarction. The intracoronary use of GPIs can be recommended as a preferred regimen during primary percutaneous coronary intervention.
机译:糖蛋白IIb / IIIa受体抑制剂(GPIs)已被广泛用作ST段抬高型心肌梗死患者初次经皮冠状动脉介入治疗期间的辅助方案,但冠状动脉内施用这些有效的抗血小板药物是否比静脉内途径具有更好的疗效和安全性尚未得到很好的解决。通过对已发表研究的系统搜索进行荟萃分析,以比较ST段抬高型心肌梗死患者冠状动脉内和静脉内给予GPI的随机对照试验。八项研究纳入了686例冠状动脉内患者和660例静脉内患者,符合纳入标准。心肌梗死(TIMI)3级血流的手术后溶栓(赔率[OR] 1.46,95%置信区间[CI] 1.08至1.98,p <0.05)和心肌再灌注2级或3级(OR 1.78,95%CI 1.29至与接受静脉注射策略的患者相比,接受冠状动脉内大剂量GPI的患者显着更多地达到2.46,p <0.001)。冠状动脉内给药可降低死亡率(OR 0.44,95%CI 0.21至0.92,p <0.05),靶血管血运重建(OR 0.53,95%CI 0.29至0.99,p <0.05)和复合终点在30天的随访中发现严重的不良心脏事件(OR 0.48,95%CI 0.31至0.76,p <0.005)。在大出血或小出血方面没有发现显着差异(分别为OR 1.14,p = 0.71和OR 0.86,p = 0.47)。总之,冠状动脉内给予GPI在ST段抬高型心肌梗死患者的术后血流恢复和30天临床预后方面取得了良好的效果。在初次经皮冠状动脉介入治疗期间,可以建议在冠状动脉内使用GPI作为首选方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号